@article {Baggottthoraxjnl-2019-214343, author = {Christina Baggott and Paul Hansen and Robert J Hancox and Jo Katherine Hardy and Jenny Sparks and Mark Holliday and Mark Weatherall and Richard Beasley and Helen K Reddel and James Fingleton}, editor = {, and , and Corin, Andrew and Dronfield, Liz and Helm, Colin and Paterson, Tracy and Poudel, Bhuwan and Sheahan, Davitt and Sheahan, Pamela and Baggott, Christina and Beasley, Richard and Braithwaite, Irene and Eathorne, Alexandra and Ebmeier, Stefan and Fingleton, James and Hall, Daniela and Hardy, Jo and Harwood, Matire and Holliday, Mark and Houghton, Claire and Mane, Saras and Martindale, John and Oldfield, Karen and Pilcher, Janine and Sabbagh, Donah and Shirtcliffe, Philippa and Sparks, Jenny and Vohlidkova, Alexandra and Williams, Mathew and Collins, Patrick and Hassan, Summer and Lam, Annika and Lionnet, Claudette and Montgomery, Barney and Smaill, Liz and Bayly-McCredie, Elena and Millar-Coote, Chris and Millar-Coote, Dean and Reid, Jim and Samuel, Anna and Hancox, Robert J and Weatherall, Mark and Reddel, Helen K}, title = {What matters most to patients when choosing treatment for mild{\textendash}moderate asthma? Results from a discrete choice experiment}, elocation-id = {thoraxjnl-2019-214343}, year = {2020}, doi = {10.1136/thoraxjnl-2019-214343}, publisher = {BMJ Publishing Group Ltd}, abstract = {Background An as-needed combination preventer and reliever regimen was recently introduced as an alternative to conventional daily preventer treatment for mild asthma. In a subgroup analysis of the PRACTICAL study, a pragmatic randomised controlled trial of budesonide{\textendash}formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild asthma, we recently reported that about two-thirds preferred as-needed combination preventer and reliever therapy. The aim of this study was to determine the relative importance of attributes associated with these two asthma therapies in this subgroup of participants who indicated their preferred treatment in the PRACTICAL study.Methods At their final study visit, a subgroup of participants indicated their preferred treatment and completed a discrete choice experiment using the Potentially All Pairwise RanKings of all possible Alternatives method and 1000minds software. Treatment attributes and their levels were selected from measurable study outcomes, and included: treatment regimen, shortness of breath, steroid dose and likelihood of asthma flare-up.Results The final analysis dataset included 288 participants, 64\% of whom preferred as-needed combination preventer and reliever. Of the attributes, no shortness of breath and lowest risk of asthma flare-up were ranked highest and second highest, respectively. However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment.Conclusions Knowledge of patient preferences for treatment attributes together with regimen characteristics can be used in shared decision-making regarding choice of treatment for patients with mild{\textendash}moderate asthma.Trial registration number ACTRN12616000377437.}, issn = {0040-6376}, URL = {https://thorax.bmj.com/content/early/2020/07/26/thoraxjnl-2019-214343}, eprint = {https://thorax.bmj.com/content/early/2020/07/26/thoraxjnl-2019-214343.full.pdf}, journal = {Thorax} }